Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Smith

Showing results (111-120 of 174) with videos related to

Pageof 18
Sort By:
Personality Disorders|January 3, 2023
BPD compass: A randomized controlled trial of a short-term, personality-based treatment for borderline personality disorderShannon Sauer-Zavala, Matthew W Southward, Martina Fruhbauerova, et al.
Journal of Agricultural and Food Chemistry|April 28, 2010
Compositions of forage and seed from second-generation glyphosate-tolerant soybean MON 89788 and insect-protected soybean MON 87701 from Brazil are equivalent to those of conventional soybean (Glycine max)Kristina H Berman, George G Harrigan, Susan G Riordan, et al.
Journal of Agricultural and Food Chemistry|November 7, 2009
Compositions of seed, forage, and processed fractions from insect-protected soybean MON 87701 are equivalent to those of conventional soybeanKristina H Berman, George G Harrigan, Susan G Riordan, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|August 21, 2023
In-Hospital Mortality Following Traumatic Injury in South AfricaErik Storm, Michelle Smith, Victor Kong, et al.
The Journal of Molecular Diagnostics : JMD|May 10, 2015
The c.1364C>A (p.A455E) Mutation in the CFTR Pseudogene Results in an Incorrectly Assigned Carrier Status by a Commonly Used Screening PlatformKristin K Deeb, James D Metcalf, Kaitlin M Sesock, et al.
Journal of Medicinal Chemistry|January 1, 2008
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activatorMartyn Frederickson, Owen Callaghan, Gianni Chessari, et al.
Molecular Cancer Therapeutics|January 29, 2009
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell linesMatthew S Squires, Ruth E Feltell, Nicola G Wallis, et al.
Cancer Research|October 28, 2016
Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung CancerSonja Schelhaas, Annelena Held, Lydia Wachsmuth, et al.
BMJ Open|April 2, 2022
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitorsGang Zhou, Nicolas Zorn, Pauline Ting, et al.
Pageof 18

Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
Personality Disorders|January 3, 2023
BPD compass: A randomized controlled trial of a short-term, personality-based treatment for borderline personality disorderShannon Sauer-Zavala, Matthew W Southward, Martina Fruhbauerova, et al.
Journal of Agricultural and Food Chemistry|April 28, 2010
Compositions of forage and seed from second-generation glyphosate-tolerant soybean MON 89788 and insect-protected soybean MON 87701 from Brazil are equivalent to those of conventional soybean (Glycine max)Kristina H Berman, George G Harrigan, Susan G Riordan, et al.
Journal of Agricultural and Food Chemistry|November 7, 2009
Compositions of seed, forage, and processed fractions from insect-protected soybean MON 87701 are equivalent to those of conventional soybeanKristina H Berman, George G Harrigan, Susan G Riordan, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|August 21, 2023
In-Hospital Mortality Following Traumatic Injury in South AfricaErik Storm, Michelle Smith, Victor Kong, et al.
The Journal of Molecular Diagnostics : JMD|May 10, 2015
The c.1364C>A (p.A455E) Mutation in the CFTR Pseudogene Results in an Incorrectly Assigned Carrier Status by a Commonly Used Screening PlatformKristin K Deeb, James D Metcalf, Kaitlin M Sesock, et al.
Journal of Medicinal Chemistry|January 1, 2008
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activatorMartyn Frederickson, Owen Callaghan, Gianni Chessari, et al.
Molecular Cancer Therapeutics|January 29, 2009
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell linesMatthew S Squires, Ruth E Feltell, Nicola G Wallis, et al.
Cancer Research|October 28, 2016
Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung CancerSonja Schelhaas, Annelena Held, Lydia Wachsmuth, et al.
BMJ Open|April 2, 2022
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitorsGang Zhou, Nicolas Zorn, Pauline Ting, et al.
Pageof 18